Seventure has appointed Danilo Casadei Massari and Dr Thomas Werner to its Health for Life Capital fund Investment Committee.
They are two very experienced figures in the international life science sector with outstanding track records which will strengthen Seventure’s team.
Casadei Massari has over 30 years of senior management experience in the pharmaceutical field and is a highly successful serial entrepreneur. Most recently he was a founder and President of CM&D Pharma Ltd, a medical food company sold to Nestle Health Science in 2011. Prior appointments include VP Corporate Development at Madaus Group, CEO of Madaus Italy, and Board positions at Fidia Farmaceutici SpA and Sinclair Pharmaceuticals Ltd. He is currently a Director on the boards of two companies in the US (Prismic Pharmaceuticals Inc and Clinical Information Network Inc) where he is a founding member, and two in Italy (Difass International Srl and InterAlia Srl). Casadei Massari is an expert in start-ups and co-ventures in the pharmaceutical sector.
Werner is an independent highly experienced industry expert for several Venture Capital and Private Equity companies in the healthcare and nutrition sectors. He acts as executive and non-executive member and chairman for numerous boards, including Basilea Pharmaceutica, Riemser Pharma, Skyepharma and BSN medical. He was also involved as Chairman of CM&D Pharma and PharmaSwiss at the time of their exit to Nestle and Valeant. He was also a member of the Board of SuppreMol until their recent acquisition by Baxter. Before then, he was a managing director at Glaxo SmithKline Germany and a Senior Vice President of GSK plc and a managing director at Bristol-Myers Squibb Germany.
Isabelle de Cremoux, President and CEO at Seventure Partners, says: “With the recent closing of the Health for Life Capital fund, the largest fund worldwide that focusses primarily on microbiome, we are looking for new investment opportunities. Danilo and Thomas’ collective international experience in the pharma, healthcare and nutrition sectors will help considerably in identifying potential new investments and advising us in our strategic approach of this booming field. We welcome them to the team.”
